Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 61

Sort by

Sort Order Select

Journal Articles

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

Blood (2011) 117 (25): 6793–6800.

https://doi.org/10.1182/blood-2011-01-328294

Published: 2011

Includes: Supplemental data

Journal Articles

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Blood (2011) 117 (21): 5591–5599.

https://doi.org/10.1182/blood-2010-12-324228

Published: 2011

Journal Articles

Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party

Blood (2010) 116 (21): 2279.

https://doi.org/10.1182/blood.V116.21.2279.2279

Published: 2010

Journal Articles

Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.

Mario Arpinati, MD, PhD, Marilina Amabile, maria Teresa Bochicchio, Angela Poerio, Giuseppe Bandini, Francesca Bonifazi, MD, Marta Stanzani, MD, PhD, Fausto Castagnetti, Gianantonio Rosti, Giovanni Martinelli, Michele Baccarani, MD

Blood (2010) 116 (21): 1287.

https://doi.org/10.1182/blood.V116.21.1287.1287

Published: 2010

Journal Articles

The Elevated Expression of FBP1 , a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Nicoletta Testoni, Marilina Amabile, Ilaria Iacobucci, Simona Soverini, Giuliana Alimena, MD, Massimo Breccia, MD, Fabrizio Pane, MD, Giuseppe Saglio, MD, PhD, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2010) 116 (21): 3399.

https://doi.org/10.1182/blood.V116.21.3399.3399

Published: 2010

Journal Articles

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Domenico Russo, Giovanni Martinelli, Michele Malagola, MD, Chiara Colombi, Giantonio Rosti, Marilina Amabile, Miriam Fogli, Diamante Turri, Salvatore Mirto, Marco Gobbi, Ivana Pierri, Umberto Vitolo, Patrizia Pregno, Enrica Morra, Ester Pungolino, Francesco Di Raimondo, Fabio Stagno, MD, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, Tamara Intermesoli, Giuseppe Saglio, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Giorgina Specchia, Vincenzo Liso, MD, Emanuele Angelucci, Emilio Usala, Caterina Musolino, MD, Sabina Russo, Gianluca Gaidano, Monia Lunghi, Francesco Lauria, Monica Bocchia, Francesco Rodeghiero, Anna D'Emilio, Alberto Bosi, Valeria Santini, Giovanni Quarta, Mariella Girasoli, Giuseppe Fioritoni, Roberto Di Lorenzo, Nicoletta Testoni, Antonio De Vivo, Simona Soverini, Ilaria Iacobucci, Michele Baccarani, Michele Baccarani

Blood (2010) 116 (21): 3412.

https://doi.org/10.1182/blood.V116.21.3412.3412

Published: 2010

Journal Articles

Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.

Simona Soverini, PhD, Angela Poerio, Caterina Debenedittis, Ilaria Iacobucci, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli, MD

Blood (2010) 116 (21): 1666.

https://doi.org/10.1182/blood.V116.21.1666.1666

Published: 2010

Journal Articles

Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay

Marco Suriano, Giovanni Martinelli, Angela Poerio, Marilina Amabile, Gianantonio Rosti, Fausto Castagnetti, Ilaria Iacobucci, Simona Soverini, Annalisa Lonetti, Cristina Papayannidis, Mariachiara Abbenante, Sarah Parisi, Francesca Palandri, Michele Baccarani, MD

Blood (2010) 116 (21): 4831.

https://doi.org/10.1182/blood.V116.21.4831.4831

Published: 2010

Journal Articles

Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial

Blood (2010) 116 (21): 359.

https://doi.org/10.1182/blood.V116.21.359.359

Published: 2010

Journal Articles

BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.

Blood (2010) 116 (21): 1230.

https://doi.org/10.1182/blood.V116.21.1230.1230

Published: 2010

Journal Articles

Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months

Michele Baccarani, Gianantonio Rosti, Giovanni Martinelli, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Nicoletta Testoni

Blood (2010) 116 (21): 668.

https://doi.org/10.1182/blood.V116.21.668.668

Published: 2010

Journal Articles

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Simona Soverini, Angela Poerio, Alberto Ferrarini, Ilaria Iacobucci, Marco Sazzini, Joannah Score, PhD, Enrico Giacomelli, Luciano Xumerle, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Marilina Amabile, Gianantonio Rosti, Michele Baccarani, Nicholas C. P. Cross, MD, Massimo Delledonne, Giovanni Martinelli

Blood (2010) 116 (21): 885.

https://doi.org/10.1182/blood.V116.21.885.885

Published: 2010

Journal Articles

First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, “Deep” and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party

Blood (2010) 116 (21): 2720.

https://doi.org/10.1182/blood.V116.21.2720.2720

Published: 2010

Journal Articles

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 − cell population with intrinsic resistance to imatinib

Roberto M. Lemoli, Valentina Salvestrini, Elisa Bianchi, Francesco Bertolini, Miriam Fogli, Marilina Amabile, Agostino Tafuri, Simona Salati, Roberta Zini, Nicoletta Testoni, Cristina Rabascio, Lara Rossi, Ines Martin-Padura, Fausto Castagnetti, Paola Marighetti, Giovanni Martinelli, Michele Baccarani, Sergio Ferrari, Rossella Manfredini

Blood (2009) 114 (25): 5191–5200.

https://doi.org/10.1182/blood-2008-08-176016

Published: 2009

Includes: Supplemental data

Journal Articles

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

Blood (2009) 114 (24): 4939–4943.

https://doi.org/10.1182/blood-2009-07-229864

Published: 2009

Includes: Supplemental data

Journal Articles

Nilotinib for the frontline treatment of Ph + chronic myeloid leukemia

Blood (2009) 114 (24): 4933–4938.

https://doi.org/10.1182/blood-2009-07-232595

Published: 2009

Journal Articles

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

Carolina Terragna, Sandra Durante, Annalisa Astolfi, Francesca Palandri, Fausto Castagnetti, Gianantonio Rosti, Nicoletta Testoni, Simona Luatti, Ilaria Iacobucci, PhD, Thea Kalebic, MD, Simona Soverini, Marilina Amabile, Angela Poerio, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2174.

https://doi.org/10.1182/blood.V114.22.2174.2174

Published: 2009

Journal Articles

High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.

Simona Soverini, PhD, Sabrina Colarossi, Alessandra Gnani, Fausto Castagnetti, Annalisa Astolfi, Serena Formica, Francesca Palandri, Ilaria Iacobucci, Gabriele Gugliotta, Angela Poerio, Marilina Amabile, Giulia Marzocchi, Nicoletta Testoni, Elisabetta Abruzzese, Gianantonio Rosti, Michele Baccarani, Giovanni Martinelli

Blood (2009) 114 (22): 2176.

https://doi.org/10.1182/blood.V114.22.2176.2176

Published: 2009

Journal Articles

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Blood (2009) 114 (22): 648.

https://doi.org/10.1182/blood.V114.22.648.648

Published: 2009

Journal Articles

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Domenico Russo, Gianantonio Rosti, Giovanni Martinelli, Michele Malagola, Salvatore Mirto, Diamante Turri, Marco Gobbi, Ivana Pierri, Umberto Vitolo, MD, Patrizia Pregno, Francesco Di Raimondo, M.D., Fabio Stagno, Robin Foà, Giuliana Alimena, Massimo Breccia, Francesco Nobile, Bruno Martino, Alessandro Rambaldi, MD, Tamara Intermesoli, Giuseppe Saglio, MD, Giovanna Rege Cambrin, Giuseppe Visani, Giuseppina Nicolini, Paolo de Fabritiis, Elisabetta Abruzzese, Renato Fanin, Mario Tiribelli, Piero Galieni, Catia Bigazzi, Vincenzo Liso, Giorgina Specchia, Emanuele Angelucci, Emilio Usala, Caterina Musolino, Sabina Russo, Gianluca Gaidano, MD, Monia Lunghi, Francesco Lauria, MD, Monica Bocchia, Francesco Rodeghiero, MD, Anna D'Emilio, MD, Giovanni Quarta, Mariella Girasoli, Alberto Bosi, Valeria Santini, Giuseppe Fioritoni, Roberto Di Lorenzo, Chiara Colombi, Miriam Fogli, Marilina Amabile, Nicoletta Testoni, Antonio De Vivo, Michele Baccarani

Blood (2009) 114 (22): 860.

https://doi.org/10.1182/blood.V114.22.860.860

Published: 2009

NARROW

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party

Long Term Study of the Impact of Quantitative Molecular Monitoring of Bcr-Abl Transcripts on the Risk of Relapse of CML After Allogeneic HSCT.

The Elevated Expression of FBP1 , a Key-Enzyme of Gluconeogenesis Gene, Is Associated to High Sokal Risk In Chronic Myeloid Leukemia Patients.

One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (≥ 65 years) Ph+ CML Patients – EudraCT Number 2007–005102-42, ClinicalTrials.Gov NCT 00858806.

Low-Level Bcr-Abl Kinase Domain Mutations Are Very Rare In Chronic Myeloid Leukemia Patients Who Are In Major Molecular Response After 12 Months of First-Line Nilotinib Therapy.

Evaluation of the GeneXpert Assay for the Monitoring of BCR-ABL Transcript Levels In Chronic Myeloid Leukemia (CML) Patients: Preliminary Results of a Comparison with the Manual and Traditional Manual TaqMan RQ-PCR Assay

Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial

BCR-ABL Fusion Transcript Do Not Significantly Influence the Outcome of Chronic Myeloid Leukemia Patients In Early Chronic Phase Treated with Imatinib Mesylate: a GIMEMA CML WP Analysis.

Evaluating the Response to Imatinib In Philadelphia-Positive Chronic Myeloid Leukemia (Ph+ CML): The Value of Major Molecular Response (MMolR) at 12 Months

Whole-Transcriptome Sequencing In Chronic Myeloid Leukemia Reveals Novel Gene Mutations That May Be Associated with Disease Pathogenesis and Progression

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34 − cell population with intrinsic resistance to imatinib

Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response: a study of the GIMEMA CML WP

Nilotinib for the frontline treatment of Ph + chronic myeloid leukemia

CD34+ obtained from High Sokal Risk Chronic Myeloid Leukemia (CML) Patients (PTS) Expresses Gene Profiles (GEP) Significantly Different From CD34+ Obtained From Low Sokal Risk Patients.

High-Resolution Molecular Allelokaryotyping of Chronic Myeloid Leukemia Patients in Blast Crisis by 6.0 SNP-Arrays Shows a High-Frequency of Uniparental Disomy and Focal Copy Number Alterations Affecting the Whole Sequence or Specific Exons of Oncogenes and Tumor Suppressor Genes.

BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial.

Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only